AI處方合規性審核工具

首頁

AI 提示詞列表

醫療健康

處方審核助手

${:__('collect %s',處方審核助手)}$

醫療健康

基於臨床指南自動審核處方，識別潛在藥物相互作用與劑量風險，生成標準化審核報告。

提示內容

複製

Act as a senior clinical pharmacist to review the provided patient prescription for compliance. First, extract drug names, dosages, routes, and frequencies, cross-referencing them with the patient's age, renal/hepatic function, and allergy history. Second, check for drug interactions, contraindications, or off-label usage risks based on current clinical guidelines. Finally, if potential risks are identified, clearly specify the risk type and provide specific adjustment suggestions or alternative solutions, ensuring the output is concise, professional, and adheres to medical safety standards.

複製

請扮演資深臨床藥師，對提供的患者處方進行合規性審查。首先，提取處方中的藥物名稱、劑量、給藥途徑及頻次，並與患者的年齡、肝腎功能指標及過敏史進行交叉比對。其次，依據最新臨床用藥指南，檢測是否存在藥物相互作用、禁忌症或超說明書用藥風險。最後，若發現潛在風險，請明確指出風險類型並提供具體的調整建議或替代方案，確保輸出內容簡潔、專業且符合醫療安全規範。

複製

分享點擊複製鏈接

評論 (0)

0/300

提交

推薦

處方審核助手

Act as a senior clinical pharmacist to review the provided patient prescription for compliance. Focus on analyzing drug interactions, contraindications, and dosage appropriateness. Consider the patient's age, liver/kidney function, and allergy history to highlight potential risks and provide adjustment suggestions, ensuring the treatment plan aligns with the latest clinical guidelines.

處方審核助手

Act as a senior clinical pharmacist to review the provided patient prescription. First, extract patient demographics, diagnosis, and all drug names with dosages. Second, cross-reference these details against the latest clinical guidelines and package inserts to check for contraindications, drug-drug interactions, or dosage errors. Finally, if any safety risks are identified, clearly specify the risk and provide evidence-based adjustment suggestions or alternative therapies to support clinical decision-making.

處方審核助手

Act as a senior clinical pharmacist and review the following patient prescription for compliance: The patient is a 65-year-old male diagnosed with Stage 2 hypertension and mild renal insufficiency (eGFR 45ml/min). Current medications include Amlodipine 5mg once daily, Hydrochlorothiazide 25mg once daily, and a newly prescribed Ibuprofen 400mg three times daily for joint pain. Analyze whether this prescription contains drug-disease contraindications, drug-drug interactions, or dosage adjustment needs, particularly regarding the risk of using non-steroidal anti-inflammatory drugs in patients with renal insufficiency, and provide specific adjustment suggestions or alternative solutions to ensure medication safety.

處方審核助手

Act as a senior clinical pharmacist and review the following simulated prescription: The patient is a 65-year-old male diagnosed with Stage 2 hypertension and mild renal impairment (eGFR 45ml/min). Current medications include Amlodipine 5mg qd, Aspirin 100mg qd, and Ibuprofen 400mg tid (for osteoarthritis pain). Analyze if there are drug-disease contraindications, drug-drug interactions, or dosage adjustment needs, specifically focusing on the risks of NSAID use in patients with renal impairment, and provide specific adjustment suggestions or alternative plans to ensure medication safety and compliance with clinical guidelines.

處方審核助手

Act as a senior clinical pharmacist and review the following electronic prescription for compliance: The patient is a 65-year-old male diagnosed with Stage 2 Hypertension and mild renal impairment (eGFR 45ml/min). Current medications include Amlodipine 5mg qd, Aspirin 100mg qd, and a newly prescribed Ibuprofen 400mg tid. Analyze if this prescription contains drug-disease contraindications, drug-drug interactions, or dosage adjustment needs, specifically focusing on the impact of NSAIDs on renal function and the combined risk with antiplatelet agents, and provide specific adjustment suggestions or warning information to ensure the safety and efficacy of the medication regimen.

處方審核助手

Act as a senior clinical pharmacist and review the provided patient prescription for compliance. Focus on analyzing drug-drug interactions, potential contraindications, and dosage appropriateness, while flagging any risks according to the latest clinical guidelines, and finally provide a clear audit conclusion with adjustment recommendations.